Cargando…
Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan
Among patients with heart failure and reduced ejection fraction (left ventricular (LV) ejection fraction ≤40%), sacubitril/valsartan (S/V) treatment is associated with improved health status and reverse cardiac remodeling. Data regarding racial and ethnic differences in response to S/V are lacking....
Autores principales: | Ibrahim, Nasrien E., Piña, Ileana L., Camacho, Alexander, Bapat, Devavrat, Felker, G. Michael, Maisel, Alan S., Butler, Javed, Prescott, Margaret F., Abbas, Cheryl A., Solomon, Scott D., Januzzi, James L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769180/ https://www.ncbi.nlm.nih.gov/pubmed/33016100 http://dx.doi.org/10.1161/CIRCHEARTFAILURE.120.007829 |
Ejemplares similares
-
Sex‐based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
por: Ibrahim, Nasrien E., et al.
Publicado: (2020) -
Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF
por: Felker, G. Michael, et al.
Publicado: (2021) -
Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure
por: Mohebi, Reza, et al.
Publicado: (2023) -
Importance of the ‘area under the curve’ from serial NT‐proBNP measurements during treatment with sacubitril/valsartan
por: Mohebi, Reza, et al.
Publicado: (2023) -
Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study
por: Januzzi, James L., et al.
Publicado: (2022)